Stocks › ALKS

Alkermes plc.

ALKS·Nasdaq·Ireland Ireland·USD
$44.94
-1.24 (-2.69%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ALKS
Alkermes plc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ALKSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ALKS by members of U.S. Congress · 2 on record · 2 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA ALKSAlkermes plc. · Stock Purchase
$1,001 - $15,000
Oct 12, 2026 Sep 29, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA ALKSAlkermes plc. · Stock Purchase
$15,001 - $50,000
Sep 4, 2026 Jul 30, 2026 Filing ↗

Whale Activity

Position changes in ALKS reported for 2026-09-30 by 467 institutional filers
Increased: 153New: 45Held: 71Decreased: 124Closed: 51No prior filing: 23
  • Increased153
  • New45
  • Held71
  • Decreased124
  • Closed51
  • No prior filing23
FilerSharesValueChange
BlackRock, Inc.28.7M$1.16Bdecreased
STATE STREET CORP10.1M$410.5Mincreased
BAKER BROS. ADVISORS LP10.0M$405.7Mheld
VANGUARD PORTFOLIO MANAGEMENT LLC9.5M$383.3Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC7.5M$304.0Mdecreased
RENAISSANCE TECHNOLOGIES LLC6.5M$263.1Mincreased
Deep Track Capital, LP4.5M$182.3Mincreased
GEODE CAPITAL MANAGEMENT, LLC4.4M$179.8Mdecreased
PRICE T ROWE ASSOCIATES INC /MD/4.0M$163.9Mdecreased
Holocene Advisors, LP3.5M$140.1Mdecreased
DIMENSIONAL FUND ADVISORS LP3.2M$127.7Mdecreased
Bain Capital Life Sciences Investors, LLC3.2M$127.7Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ALKS insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -457.3K2025 Q12025 Q2: -6,6672025 Q22025 Q3: 02025 Q32025 Q4: -25.7K2025 Q42026 Q1: -105.2K2026 Q12026 Q2: -51.3K2026 Q22026 Q3: -85.2K2026 Q32026 Q4: -4,0692026 Q4

Recent Insider Transactions

3,249 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Gaffin David JosephEVP, CLO, Alkermes, Inc. Sale −2,035 $46.17 $94K Nov 3, 2026 Form 4 ↗
Gaffin David JosephEVP, CLO, Alkermes, Inc. Sale −2,034 $41.03 $83K Oct 2, 2026 Form 4 ↗
Gaffin David JosephEVP, CLO, Alkermes, Inc. Sale −2,034 $48.01 $98K Sep 3, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Sale −9,000 $46.99 $423K Sep 1, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Option exercise +5,000 $24.59 $123K Sep 1, 2026 Form 4 ↗
Nichols Christian ToddSVP, Chief Commercial Officer Sale −664 $49.65 $33K Aug 17, 2026 Form 4 ↗
Nichols Christian ToddSVP, Chief Commercial Officer Sale −6,912 $49.19 $340K Aug 17, 2026 Form 4 ↗
snyderman nancy lynn MDDirector Sale −44.5K $50.35 $2.2M Aug 3, 2026 Form 4 ↗
snyderman nancy lynn MDDirector Option exercise +16.5K $46.72 $772K Aug 3, 2026 Form 4 ↗
snyderman nancy lynn MDDirector Option exercise +27.9K $46.72 $1.3M Aug 3, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Sale −9,000 $48.58 $437K Aug 3, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Option exercise +4,896 $24.59 $120K Aug 3, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Option exercise +104 $19.34 $2K Aug 3, 2026 Form 4 ↗
Gaffin David JosephEVP, CLO, Alkermes, Inc. Sale −2,034 $48.58 $99K Aug 3, 2026 Form 4 ↗
Gaffin David JosephEVP, CLO, Alkermes, Inc. Sale −2,034 $54.03 $110K Jul 6, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Sale −700 $52.13 $36K Jul 1, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Sale −8,300 $51.46 $427K Jul 1, 2026 Form 4 ↗
Hopkinson Craig C.EVP R&D, Chief Medical Officer Option exercise +5,000 $19.34 $97K Jul 1, 2026 Form 4 ↗
Wright Christopher IDirector Sale −2,000 $45.10 $90K Jun 12, 2026 Form 4 ↗
Gaffin David JosephEVP, CLO, Alkermes, Inc. Sale −2,034 $43.05 $88K Jun 4, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ALKS · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
5.3M$277.6M0.01%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.8M$200.3M0.11%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
2.2M$115.4M0.25%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.9M$100.2M0.10%Jun 30, 2026
VANGUARD CAPITAL OPPORTUNITY FUND
VANGUARD HORIZON FUNDS
1.7M$89.9M0.27%Jun 30, 2026
VANGUARD TAX-MANAGED SMALL-CAP FUND
VANGUARD TAX-MANAGED FUNDS
1.1M$56.4M0.49%Jun 30, 2026
Small Cap Growth Fund
American Century Mutual Funds, Inc.
993.4K$48.7M0.87%Jul 31, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
960.9K$45.2M0.25%Aug 31, 2026
College Retirement Equities Fund - Total Global Stock Account
College Retirement Equities Fund
703.1K$36.8M0.03%Jun 30, 2026
Avantis U.S. Small Cap Value ETF
American Century ETF Trust
680.8K$32.0M0.10%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list ALKS's shares (CUSIP G01767105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 4.7M shares2.8%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming alkermes as client
$0$2.5M$5.0M$7.5M$10.0M2023 Q1: $2.2M2023 Q2: $1.0M2023 Q3: $875K2023 Q4: $920K20232024 Q1: $1.3M2024 Q2: $800K2024 Q3: $920K2024 Q4: $800K20242025 Q1: $1.9M2025 Q2: $1.4M2025 Q3: $1.5M2025 Q4: $1.5M20252026 Q1: $1.5M2026 Q2: $1.6M2026 Q3: $1.7M2026
  • HEALTH AND MEDICINE COUNSELALKERMES, INC · 2026 Q3 · HCR, BUD$10K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSALKERMES, INC. · 2026 Q3 · HCR$50K
    Filing ↗
  • TODD STRATEGY GROUPALKERMES, INC. · 2026 Q3 · HCR, MMM$60K
    Filing ↗
  • HEALTH AND MEDICINE COUNSELALKERMES, INC · 2026 Q2 · BUD, HCR—
    Filing ↗
  • ALKERMES, INC.ALKERMES, INC. · 2026 Q3 · MMM, HCR, ALC, TAR$970K
    Filing ↗

Government Contracts

Federal awards to Alkermes plc. · USAspending

No federal contract awards found for Alkermes plc..

U.S. Patents

Recent USPTO applications naming Alkermes plc.

No USPTO patent applications found for Alkermes plc..

Annual Financials

From ALKS's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$1.48B$1.56B$1.66B$1.11B$1.17B
Operating income$254.0M$420.6M$414.1M-$6.1M$97.7M
Net income$241.7M$367.1M$355.8M-$158.3M-$48.2M
Diluted EPS$1.43$2.17$2.10-$0.97-$0.29
Operating cash flow$520.8M$439.1M$401.4M$21.0M$101.7M
Cash and equivalents$388.6M$291.1M$457.5M$292.5M$337.5M
Total assets$2.49B$2.06B$2.14B$1.96B$2.02B
Total liabilities$667.7M$590.6M$933.5M$920.2M$911.9M
Shareholders' equity$1.82B$1.46B$1.20B$1.04B$1.11B

As Alkermes plc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 2-for-1Stock splitMay 15, 2000

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 1.01Material agreementNov 12, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 3, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 21, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 16, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 9.01Material agreementAug 12, 2026
    EDGAR ↗
  • 8-K/A · Items 5.02Officer / director changeAug 3, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
    EDGAR ↗
  • 8-K · Items 1.02Termination of agreementJul 8, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 20, 2026
    EDGAR ↗

About Alkermes plc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersDUBLIN 4, Ireland
Former namesANTLER SCIENCE TWO PLC, Antler Science Two Ltd